Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS known ✓ | P04818 | 6/20 | 0.56 |
| ▸ | DHFR known ✓ | P00374 | 11/20 | 0.54 |
| ▸ | GART known ✓ | P22102 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.47 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.47 |
| ▸ | ATIC | P31939 | 1/20 | 0.47 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.47 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.47 |
| ▸ | FRK | P42685 | 1/20 | 0.47 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801501 | 0.86 | DHFR (0.63) | TYMSDHFRNAMPTFOLR2FOLR1 | |
| SCHEMBL13971 | 0.86 | DHFR (0.63) | TYMSDHFRNAMPTFOLR2FOLR1 | |
| SCHEMBL1798861 | 0.85 | DHFR (0.62) | TYMSDHFRNAMPTFOLR2FOLR1 | |
| SCHEMBL1798854 | 0.85 | DHFR (0.62) | TYMSDHFRNAMPTFOLR2FOLR1 | |
| SCHEMBL12559684 | 0.84 | DHFR (0.63) | TYMSDHFRNAMPTFOLR2FOLR1 | |
| SCHEMBL12559669 | 0.81 | DHFR (0.64) | TYMSDHFRNAMPTFOLR2FOLR1 | |
| SCHEMBL12616064 | 0.81 | DHFR (0.64) | TYMSDHFRNAMPTFOLR2FOLR1 | |
| SCHEMBL12559664 | 0.81 | DHFR (0.56) | TYMSDHFRNAMPTFOLR2FOLR1 | |
| SCHEMBL7848195 | 0.78 | DHFR (0.84) | TYMSDHFRNAMPTFOLR2FOLR1 | |
| SCHEMBL12597980 | 0.77 | DHFR (0.55) | TYMSDHFRNAMPTFOLR2FOLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | Chelsea Thereapeutics, Inc. | 2011-06-23 | — | — | US | disclosed |
| US-7951812-B2 | For abnormal cell proliferation, inflammatory diseases, asthma, and arthritis; (S)-N-{4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-4-methylene-L-glutamic acid disodium salt (CHL1007) | CHELSEA THERAPEUTICS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | CHELSEA THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152276-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES AS ANTIFOLATES | CCR9, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNO | TYMS 154/4885DHFR 105/4885GART 625/4885 |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | FFAR3, CCR9, NR1H3 | TYMS 1972/4885DHFR 517/4885GART 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.